• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Trump to meet with biotech execs, researchers to discuss federal funding

April 24, 2017 By Sarah Faulkner

capitol hillIn the wake of President Donald Trump’s $6 billion proposed cut to the National Institutes of Health, biotech executives and researchers are slated to meet with the new administration next month.

A memo about the meeting reportedly describes the get-together as a chance for the “private sector and thought leaders to describe their institution and its connection to federal funding.”

Vice President Mike Pence, Ivanka Trump and Jared Kushner plan to attend the summit, Bloomberg reported, along with top NIH officials, researchers from universities and hospitals across the U.S., and executives from Celgene and Regeneron Pharmaceuticals.

Regeneron’s chief executive, Len Schleifer, has spoken regularly about the importance of drug pricing reform in the industry – a topic which Trump has seemingly taken an interest in. He once said the industry was “getting away with murder” in regards to what it charges for its products.

Other summit participants include Health and Human Services secretary Tom Price and Vertex Pharmaceuticals’ CEO Jeff Leiden.

Francis Collins, head of the NIH, is also scheduled to attend the meeting. The NIH provides funding to many top research institutions across the country, such as the 321 grants worth $138 million that it has awarded to Stanford University. The university’s president, Marc Tessier-Lavigne, is listed on the meeting’s agenda.

Pharma stocks fell last month after the Trump administration revealed their proposed budget, which would slash more than 18% from the NIH.

The proposal would also introduce “a major reorganization of NIH’s Institutes and Centers to help focus resources on the highest priority research and training activities.”

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: National Institutes of Health

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS